Loading...
Loading...
Dilation agents are among the most frequently used medications in ophthalmology. Every dilated fundus exam, cycloplegic refraction, and uveitis treatment involves pharmacological manipulation of the iris and ciliary body. For COA candidates, the Pharmacology domain tests knowledge of which agents dilate only versus dilate and paralyze accommodation, their onset and duration, their contraindications, and how to manage patient expectations and safety during and after dilation.
The fundamental distinction is between mydriatics — agents that dilate the pupil through adrenergic stimulation of the iris dilator muscle — and cycloplegics — anticholinergic agents that dilate the pupil and simultaneously paralyze the ciliary muscle, abolishing accommodation. This distinction drives clinical decision-making: a routine dilated fundus exam uses a mydriatic combination, while a cycloplegic refraction in a child requires a true cycloplegic.
Stimulate alpha-1 adrenergic receptors on the iris dilator (dilator pupillae) muscle, causing active contraction of the dilator and pupil dilation.
Block muscarinic (M3) receptors on both the iris sphincter and ciliary muscle, paralyzing pupil constriction and accommodation simultaneously.
In children especially, the ciliary muscle can actively accommodate even during refraction attempts, masking latent hyperopia (farsightedness). Without cycloplegia, the ciliary muscle contracts to partially compensate for hyperopia, producing a refraction that underestimates the true plus power needed. A cycloplegic refraction paralyzes this accommodation, revealing the full refractive error. This is why cycloplegic refraction is the standard of care for pediatric refractive assessment and is critical before prescribing glasses for children with suspected accommodative esotropia.
| Agent | Class | Onset | Duration | Cycloplegia | Primary Use |
|---|---|---|---|---|---|
| Phenylephrine 2.5% | Alpha-1 agonist | 15–20 min | 4–6 hours | None | Routine dilation (safe in cardiac patients) |
| Phenylephrine 10% | Alpha-1 agonist | 10–15 min | 4–6 hours | None | Dark irides; avoid in elderly/cardiac disease |
| Tropicamide 0.5% | Anticholinergic | 15–20 min | 4–6 hours | Minimal | Fundus exam, ophthalmoscopy |
| Tropicamide 1% | Anticholinergic | 15–20 min | 6–8 hours | Mild | Routine dilation; weak cycloplegia in adults |
| Cyclopentolate 0.5% | Anticholinergic | 25–75 min | 24 hours | Moderate–Strong | Pediatric cycloplegic refraction (young children) |
| Cyclopentolate 1% | Anticholinergic | 25–75 min | 24 hours | Strong | Standard pediatric cycloplegic refraction |
| Atropine 1% | Anticholinergic | 30–90 min | 7–14 days | Maximum | Complete cycloplegia; uveitis; dark irides in children |
| Homatropine 2–5% | Anticholinergic | 30–60 min | 1–3 days | Moderate | Uveitis; moderate duration needed |
Phenylephrine is a selective alpha-1 adrenergic agonist that stimulates the dilator pupillae muscle. It provides excellent pupil dilation without any effect on accommodation or the ciliary muscle — patients retain their near vision (though vision may be blurred from the dilated pupil's reduced depth of focus). The 2.5% concentration is the standard for routine use in adults. The 10% concentration is reserved for patients who do not dilate adequately with 2.5%, particularly those with heavily pigmented irides.
Tropicamide is the most commonly used cycloplegic agent for routine fundus examination in adults. It is a short-acting muscarinic antagonist with rapid onset (about 20 minutes) and a relatively short duration (6–8 hours), making it practical for outpatient exams — patients can often drive themselves home within a few hours if vision has sufficiently recovered. The 0.5% concentration provides good dilation with minimal cycloplegia; the 1% concentration adds mild cycloplegia. Neither concentration provides complete cycloplegia, making tropicamide unsuitable for definitive cycloplegic refraction in children or highly accommodative adults.
Standard routine dilation protocol: tropicamide 1% + phenylephrine 2.5%, one drop each, repeated in 5 minutes, with dilation expected in 20–30 minutes.
Cyclopentolate is the preferred cycloplegic for pediatric refractions. It provides strong cycloplegia (cyclopentolate 1% achieves near-complete paralysis of accommodation in most children within 30–45 minutes) with a duration of approximately 24 hours. Two drops instilled 5 minutes apart maximize cycloplegia. In young infants and neonates, the 0.5% concentration reduces the risk of systemic toxicity.
Atropine provides the most complete and prolonged cycloplegia of any topical agent. Duration of 7–14 days makes it ideal for conditions requiring sustained pupil dilation (posterior uveitis to prevent synechiae, iridocyclitis) and for detecting the full refractive error in children with very high accommodative tone, amblyopia treatment, or in those with very dark irides in whom cyclopentolate may not provide complete cycloplegia.
For atropine cycloplegic refraction, drops are instilled at home 1–3 times per day for 3 days before the refraction appointment, with a warning that effects persist for 1–2 weeks.
Dilating a patient with a narrow anterior chamber angle can precipitate acute angle-closure glaucoma — an ocular emergency. The dilated pupil causes the iris to bow forward, physically obstructing the trabecular meshwork and causing a sudden, dramatic rise in IOP.
Dapiprazole (Rev-Eyes) is an alpha-adrenergic blocker that can reverse the mydriatic component of dilation by blocking alpha-1 receptors on the dilator muscle and allowing the iris sphincter to constrict. It reduces dilation time by approximately 1–2 hours but cannot reverse cycloplegia (which must wear off naturally). Dapiprazole is rarely used in modern practice because it causes significant conjunctival hyperemia (redness) and does not fully reverse the cycloplegic component. Patients are typically simply advised to wait for dilation to reverse naturally. Some patients may benefit from dapiprazole if they need to resume driving or close work sooner.
Children and Infants
Use cyclopentolate 0.5% in infants under 3 months (lower systemic dose). Cyclopentolate 1% for older children. Atropine 0.5% ointment for amblyopia penalization. Always use punctal occlusion and eyelid closure after instillation to minimize systemic absorption. Warn parents about CNS effects from cyclopentolate and anticholinergic signs from atropine.
Elderly Patients
The elderly may have reduced pupil dilation response due to age-related iris atrophy and sympathetic decline. Use phenylephrine 2.5% (not 10%) to minimize cardiovascular risk. Warn about fall risk from near-vision blur and photophobia during dilation. Elderly patients may already have some degree of natural pupil miosis and may require longer to dilate.
Darkly Pigmented Irides
Melanin in highly pigmented irides binds mydriatic/cycloplegic drugs, reducing efficacy. A second drop instilled 5–10 minutes after the first helps overcome this. For children with very dark irides and inadequate cycloplegia from cyclopentolate, atropine is used. Adding phenylephrine 2.5% to the cycloplegic regimen provides additional dilator stimulation.
Patients with Iris-Supported Lenses or Angle Clips
Patients with certain anterior chamber IOLs, iris clip lenses (Artisan/Verisyse), or transscleral-fixated lenses may have contraindications to strong dilation. Consult the surgeon's notes and physician before dilating post-surgical eyes with unusual anterior segment anatomy.
Document in the chart:
Advise the patient:
Opterio includes dilation agent questions within the COA Pharmacology domain, with AI explanations that reinforce mechanism, contraindication logic, and special population management.
Proparacaine vs tetracaine, mechanism, clinical uses, and toxic keratopathy warning.
All five drug classes with mechanisms, dosing, side effects, and compliance tips.
Systemic absorption risks, allergic vs toxic reactions, and documentation requirements.
Exam format, content domains, eligibility, pass rates, and registration guide.
A mydriatic causes pupil dilation (mydriasis) by stimulating the iris dilator muscle, but has no significant effect on the ciliary muscle and therefore does not impair accommodation. Phenylephrine is the classic mydriatic — it activates alpha-1 adrenergic receptors on the dilator pupillae. A cycloplegic both dilates the pupil AND paralyzes the ciliary muscle (cycloplegia), eliminating the accommodative reflex. Cycloplegics are muscarinic antagonists (anticholinergics) that block the acetylcholine receptors on both the iris sphincter (causing dilation) and the ciliary muscle (causing cycloplegia). Examples include tropicamide, cyclopentolate, and atropine. For a complete cycloplegic refraction, a true cycloplegic must be used.
The most common combination for a routine dilated fundus examination in an adult is tropicamide 1% plus phenylephrine 2.5%. Tropicamide provides dilation and mild cycloplegia (enough to reduce the light reflex for fundus viewing), while phenylephrine provides additional dilator stimulation for larger pupil size, particularly in patients with dark irides who dilate poorly with tropicamide alone. This combination typically achieves adequate dilation within 20–30 minutes. For pediatric cycloplegic refraction, cyclopentolate 1% is preferred due to its more complete and faster cycloplegia than tropicamide.
Phenylephrine 10% is a potent alpha-1 adrenergic agonist that, after instillation, can be absorbed systemically via the nasolacrimal duct. The resulting systemic alpha-1 stimulation can cause acute hypertension, reflex bradycardia, and rarely severe cardiovascular events including myocardial infarction and stroke. For this reason, phenylephrine 10% is relatively contraindicated in patients with cardiovascular disease, uncontrolled hypertension, severe atherosclerosis, and the elderly. The 2.5% concentration achieves adequate dilation with a much lower risk of systemic effects. Pediatric use of phenylephrine 10% is also avoided due to the higher risk of systemic absorption in children.
Before dilating any patient, the COA should screen for signs of narrow anterior chamber angles, which carry a risk of angle closure precipitated by pupil dilation. Risk factors include: age over 60, hyperopic refraction (plus power), Asian descent, shallow anterior chamber on penlight oblique illumination, and positive history of eye pain with halos. The penlight shadow test (Van Herrick technique) can suggest a shallow angle. However, definitive angle assessment requires gonioscopy or anterior segment OCT — both physician procedures. The COA should document the screen, note any risk factors, and alert the physician before dilation in high-risk patients. Patients with an established diagnosis of open-angle glaucoma can generally be dilated safely.
Iris pigmentation (melanin) binds some mydriatic and cycloplegic drugs, reducing their effective concentration at the receptor level. Patients with heavily pigmented (dark brown) irides dilate less completely and more slowly than those with blue or hazel irides using the same agent and dose. To achieve adequate dilation, a second drop may be instilled 5–10 minutes after the first, or a stronger agent (e.g., phenylephrine 2.5% added to tropicamide) may be used. For cycloplegic refractions in patients with dark irides, cyclopentolate 1% may need to be supplemented or atropine may be required in very dark eyes, particularly in children.